



(12) Translation of
European patent specification

(11) NO/EP 3630164 B1

NORWAY

(19) NO
(51) Int Cl.

A61K 38/26 (2006.01)

A61K 38/28 (2006.01)

A61K 45/06 (2006.01)

A61P 13/12 (2006.01)

G01N 33/68 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2023.10.16
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.08.23
(86)	European Application Nr.	18730908.3
(86)	European Filing Date	2018.05.24
(87)	The European Application's Publication Date	2020.04.08
(30)	Priority	2017.06.01, US, 201762513556 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
(72)	Inventor	BOTROS, Fady Talaat, c/o Eli Lilly and Company P.O. Box 6288, Indianapolis, Indiana 46206-6288, USA LAKSHMANAN, Mark Chandrakant, c/o Eli Lilly and Company P.O. Box 6288, Indianapolis, Indiana 46206-6288, USA TUTTLE, Katherine Rose, c/o Eli Lilly and Company P.O. Box 6288, Indianapolis, Indiana 46206-6288, USA ZIMMERMANN, Alan George, c/o Eli Lilly and Company P.O. Box 6288, Indianapolis, Indiana 46206-6288, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	DULAGLUTIDE FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE
------	-------	--

(56)	References Cited:
------	----------------------

WO-A1-2011/138421

MELANIE DAVIES ET AL: "The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies", CLINICAL PHARMACOLOGY: ADVANCES AND APPLICATIONS, vol. 8, 23 June 2016 (2016-06-23), pages 61-81, XP055497212, DOI: 10.2147/CPAA.S82008

KATHERINE R TUTTLE ET AL: "Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial", THE LANCET / DIABETES & ENDOCRINOLOGY, vol. 6, no. 8, 1 August 2018 (2018-08-01), pages 605-617, XP055497169, UK ISSN: 2213-8587, DOI: 10.1016/S2213-8587(18)30104-9

K R TUTTLE ET AL: "Comparable glycaemic control with once weekly dulaglutide versus insulin glargine, both combined with lispro, in type 2 diabetes and chronic kidney disease (AWARD-7)",

DIABETOLOGIA, vol. 60, no. Suppl. 1, 11 September 2017 (2017-09-11), page S3, XP055497178, BERLIN, DE ISSN: 0012-186X, DOI: 10.1007/s00125-017-4350-z

LILI TONG ET AL: "Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers", POSTGRADUATE MEDICINE., vol. 130, no. 4, 19 May 2018 (2018-05-19), pages 381-393, XP055497193, US ISSN: 0032-5481, DOI: 10.1080/00325481.2018.1457397

Anonymous: "A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)", , 18 June 2012 (2012-06-18), XP055497221, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/NC_T01621178 [retrieved on 2018-08-03]

KATHERINE R. TUTTLE ET AL: "Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials", DIABETES, OBESITY AND METABOLISM, vol. 19, no. 3, 23 November 2016 (2016-11-23), pages 436-441, XP055497173, ISSN: 1462-8902, DOI: 10.1111/dom.12816 cited in the application

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Dulaglutid for bruk ved behandling av kronisk nyresykdom (CKD) hos en pasient, hvor pasienten har:
 - a) estimert glomerulær filtrasjonshastighet (eGFR) mellom 15-89 mL/min/1,73 m²; og
 - 5 b) urin-albumin (mg/dl) til urinkreatin (g/dl) (UACR) høyere enn 300 mg/g;hvor en virksam mengde av dulaglutid blir administrert én gang i uken i minst 6 måneder; og hvor dulaglutid blir administrert i en dose på 1,5 mg.
- 10 2. Dulaglutid for bruk ifølge krav 1 hvor pasientens kroniske nyresykdom ikke er forårsaket av diabetes mellitus type 2.
3. Dulaglutid for bruk ifølge krav 1 hvor pasientens kroniske nyresykdom er forårsaket av diabetes mellitus type 2.
- 15 4. Dulaglutid for bruk ifølge et hvilket som helst av kravene 1 til 3 hvor pasienten har nyreskade med eGFR mellom 60-89 mL/min/1,73 m².
5. Dulaglutid for bruk ifølge et hvilket som helst av kravene 1 til 4 hvor pasienten har nyreskade med eGFR mellom 60-75 mL/min/1,73 m².
- 20 6. Dulaglutid for bruk ifølge krav 4 eller krav 5, hvor administreringen fortsettes i minst 1 år.